News

Immune restraint through the ages: PD-1 pathway traced to sharks
In 1992, graduate student Yasumasa Ishida discovered PD-1, marking the beginning of a journey that would make this molecule a ...
BioSpace11h
Summit’s Bispecific Misses Survival Endpoint in Global Phase III Trial but Analysts Remain Optimistic
Despite mixed results, analysts maintained faith in ivonescimab’s ability to cross over between Eastern and Western patient ...
ascopubs.org23h
First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PD-L1 status.
Molecular characterization of an extensive lung cancer patient-derived xenograft (PDX) resource.